1085458-48-5

Basic information

• Product Name: 2(1H)-Quinazolinone, 6-fluoro
• Synonyms: 2(1H)-Quinazolinone, 6-fluoro;6-fluoro-2(1H)-Quinazolinone;6-fluoroquinazolin-2(1H)-one
• CAS NO: 1085458-48-5
• Molecular Formula: C₈H₅FN₂O
• Molecular Weight: 164.1365032
• Mol File: 1085458-48-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Quinazolinone, 6-fluoro(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinazolinone, 6-fluoro(1085458-48-5)
• EPA Substance Registry System: 2(1H)-Quinazolinone, 6-fluoro(1085458-48-5)

Safety Data

• Hazardous Substances Data: 1085458-48-5(Hazardous Substances Data)

Usage

Structure

Bicyclic compound with a quinazoline core and a fluorine atom at the 6-position

Derivative of

Quinazolinone

Pharmaceutical applications

Potential use in the development of new drugs for various therapeutic purposes

Biological and pharmacological activities

Not extensively studied, but may have interesting interactions with biological systems due to its fluorinated structure

Organic synthesis

May be used as a building block for the preparation of other fluorinated compounds

Interest

Compound of interest for pharmaceutical and chemical applications.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 603306-58-7 2-(dibutoxymethyl)-4-fluoro-1-nitrobenzene 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 146829-56-3 2-amino-5-fluoro benzaldehyde 
• 57-13-6 urea 
• 391-93-5 ethyl 2-amino-5-fluorobenzoate 
• 77287-34-4 formamide 

Downstream Products

• 113082-27-2 2-chloro-6-fluoroquinazoline 
• 1085458-32-7 3-(6-fluoroquinazolin-2-yl)-10-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 16499-45-9 7-fluoroquinazoline 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia

Despite increased understanding of the biological basis for sleep control in the brain, few novel mechanisms for the treatment of insomnia have been identified in recent years. One notable exception is inhibition of the excitatory neuropeptides orexins A and B by design of orexin receptor antagonists. Herein, we describe how efforts to understand the origin of poor oral pharmacokinetics in a leading HTS-derived diazepane orexin receptor antagonist led to the identification of compound 10 with a 7-methyl substitution on the diazepane core. Though 10 displayed good potency, improved pharmacokinetics, and excellent in vivo efficacy, it formed reactive metabolites in microsomal incubations. A mechanistic hypothesis coupled with an in vitro assay to assess bioactivation led to replacement of the fluoroquinazoline ring of 10 with a chlorobenzoxazole to provide 3 (MK-4305), a potent dual orexin receptor antagonist that is currently being tested in phase III clinical trials for the treatment of primary insomnia.

OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.